Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on TERN stock, giving a Buy rating on April 30. Graig ...

Tremendous advances have been made in the discovery of novel ligands for G-protein-coupled receptors (GPCRs) that act at allosteric sites to regulate receptor function. Small molecules can act at ...

Addex Therapeutics’ run of bad luck in the clinic shows no sign of ending, as a Janssen-licensed epilepsy drug has failed to ...

Addex and J&J co-developed the allosteric modulator therapy which failed to meet the primary endpoint in a Phase II epilepsy ...

NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched ...

That is, high-CBD genetics, to clean up the effects of THC a bit. Because cannabidiol is an allosteric modulator: it's as if cannabidiol prevents THC from interacting with the receptors,” details ...

A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Phase 1 clinical trial supported by preclinical profile ...

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex ...

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

Q1 2024 Earnings Call Transcript May 1, 2024 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0 ...

Johnson & Johnson and Addex Therapeutics’ epilepsy hopeful ADX71149 did not meet its primary endpoint of time to reach ...

STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug interaction (DDI) ...